<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30652742</article-id><article-id pub-id-type="pmc">6326442</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2018-0130</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Which Method to Use for Surgical Ablation of Atrial Fibrillation
Performed Concomitantly with Mitral Valve Surgery: Radiofrequency Ablation
<italic>versus</italic> Cryoablation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Vural</surname><given-names>&#x000dc;nsal</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Balc&#x00131;</surname><given-names>Ahmet Yavuz</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>A&#x0011f;lar</surname><given-names>Ahmet Arif</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>K&#x00131;z&#x00131;lay</surname><given-names>Mehmet</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><aff id="aff1">
<label>1</label> Department of Cardiovascular Surgery, Dr. Siyami Ersek Thoracic
and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey.
</aff></contrib-group><author-notes><corresp id="c1">Correspondence Address: &#x000dc;nsal Vural, Selimiye Mh. Tibbiye
Cd. No:13, 34668 - Uskudar, Istanbul, Turkey. E-mail:
<email>unsalvural@gmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Nov-Dec</season><year>2018</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Nov-Dec</season><year>2018</year></pub-date><volume>33</volume><issue>6</issue><fpage>542</fpage><lpage>552</lpage><history><date date-type="received"><day>05</day><month>5</month><year>2018</year></date><date date-type="accepted"><day>08</day><month>7</month><year>2018</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>The effects of energy source on the maintenance of sinus rhythm and the
contribution of demographic characteristics to the case selection in
patients submitted to ablation performed concurrently with mitral valve
surgery were analyzed.</p></sec><sec><title>Methods</title><p>Cryothermal (n=42; 43.8%) and radiofrequency (n=54; 56.3%) energy were
employed in 96 patients submitted to mitral valve replacement and Cox maze
IV procedure. Patients were called for control visits between 15 days and 12
months after discharge. The causal relationship between recurrence of atrial
fibrillation and factors such as left atrial diameter, C-reactive protein,
hypertension, left ventricular ejection fraction, chronic obstructive
pulmonary disease, and body mass index was determined.</p></sec><sec><title>Results</title><p>Maintenance rates of the sinus rhythm with radiofrequency and cryoablation
were 97.6% and 96.3%, respectively, in the first postoperative month,
whereas at the 12<sup>th</sup> postoperative month were 88.1% and 83.3%. No
significant difference was found between groups in relation to the energy
source. Sensitivity and specificity for left atrial diameter with a cut-off
value of 50.5 mm were 85.7% and 70.7%, respectively. Sensitivity and
specificity for C-reactive protein with a cut-off value of 12 mg/dL on the
15<sup>th</sup> postoperative day were 83.3% and 88.9%, respectively.
The effect of body mass index on atrial fibrillation recurrence was 3.2
times. Sensitivity and specificity for left ventricular ejection fraction
37% cut-off value were 96.3% and 11.4%, respectively. Atrial fibrillation in
hypertensive cases was 5.3 times more. In patients with chronic obstructive
pulmonary disease, recurrence of atrial fibrillation was 40%. The causal
relation between recurrence of atrial fibrillation and the studied factors
was established.</p></sec><sec><title>Conclusion</title><p>Demographic characteristics have a significant impact on ablation efficiency,
while the type of energy source does not.</p></sec></abstract><kwd-group><kwd>Mitral Valve/surgery</kwd><kwd>Cryosurgery</kwd><kwd>Catheter Ablation</kwd><kwd>Ablation</kwd><kwd>Ablation Techniques</kwd></kwd-group></article-meta></front><body><table-wrap id="t3" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="38%" span="1"/><col width="05%" span="1"/><col width="10%" span="1"/><col width="37%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#eaeaea" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" colspan="2" style="background-color:#eaeaea" rowspan="1">&#x000a0;</th></tr></thead><tbody><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>AF</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Atrial
fibrillation</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>ECG</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>=
Electrocardiogram</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>ACC</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= American College
of Cardiology</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>EHRA</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= European Heart
Rhythm Association</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>AHA</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= American Heart
Association</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>ESC</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= European Society
of Cardiology</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>BMI</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Body mass
index</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>HRS</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Heart Rhythm
Society</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>COPD</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Chronic
obstructive pulmonary disease</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>LVEF</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Left ventricular
ejection fraction</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>CrA</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Cryothermal
ablation</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>RFA</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Radiofrequency
ablation</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>CRP</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= C-reactive
protein</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>ROC</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Receiver operating
characteristic</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>ECAS</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= European Cardiac
Arrhythmia Society</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Atrial fibrillation (AF) is the most common cause of arrhythmia and its incidence
increases with age. The prevalence in developed countries is 1.5-2%. It reaches 17%
in advanced age and 80% for mitral valve disease<sup>[</sup><sup><xref rid="r1" ref-type="bibr">1</xref></sup><sup>]</sup>. It increases the risk
of thromboembolism by sixteen times (the incidence of stroke is 5-10% in patients
with AF whereas it is 0.3% in the normal population)<sup>[</sup><sup><xref rid="r2" ref-type="bibr">2</xref></sup><sup>]</sup>. It is known that
cardiovascular mortality is doubled by AF<sup>[</sup><sup><xref rid="r2" ref-type="bibr">2</xref></sup><sup>]</sup>. According to the American Heart
Association (AHA), 70,000 patients a year are referred to hospitals due to
AF<sup>[</sup><sup><xref rid="r2" ref-type="bibr">2</xref></sup><sup>]</sup>.
Additional complications such as hemodynamic instability, palpitation, fainting,
increased duration of total hospitalization, and side effects due to pharmacological
treatment applied are also observed<sup>[</sup><sup><xref rid="r3" ref-type="bibr">3</xref></sup><sup>]</sup>. For this reason, the Heart Rhythm Society
(HRS)/ European Heart Rhythm Association (EHRA)/ European Cardiac Arrhythmia Society
(ECAS) guidelines recommend treatment of AF with ablation if cardiac surgery is
performed for concomitant pathology<sup>[</sup><sup><xref rid="r4" ref-type="bibr">4</xref></sup><sup>]</sup>.</p><p>Since Cox's surgical AF ablation reported the cut-and-sew technique in 1987, only 38%
of the valve replacement procedures have been coupled with AF
ablation<sup>[</sup><sup><xref rid="r5" ref-type="bibr">5</xref></sup><sup>]</sup>. Although it was reported in the first years that
sinus rhythm and conduction pathways were preserved, this did not relieve surgeon's
concerns. In the following years, there was renewed interest among surgeons for maze
procedure, after reporting that alternative sources of energy
(<italic>e.g</italic>., radiofrequency, ultrasound and cryothermal) could create
transmural lesions. The purpose of the ablation is to synchronize the atrium and the
ventricles by inhibiting reentry in macroreentrant circuits and reducing the surface
area to which the electrical activity of the atrium is confined, in addition to
ablation of focal atrial triggers<sup>[</sup><sup><xref rid="r6" ref-type="bibr">6</xref></sup><sup>]</sup>. In order to the procedure to be effective, it
is important to create transmural lesions, not disrupt the atrium functions and
damage surrounding tissues<sup>[</sup><sup><xref rid="r7" ref-type="bibr">7</xref></sup><sup>]</sup>.</p><p>Although there are many studies showing the success of the Cox maze IV method, only a
small number of studies comparing energy sources and focused on the causes of AF
recurrence is present. Despite the initial successful results with bipolar cautery,
it had disadvantages such as difficulties in handling and controlling energy, clot
formation in the atrium, rupture of the atrium, and damage to surrounding tissues.
Due to the risk of esophageal and coronary artery injury, in particular, the method
has gradually given way to the radiofrequency ablation (RFA). Radiofrequency is a
hyperthermic energy, producing transmural lesions. Alternatively, cryothermal
ablation (CrA) produces lesions similar to the classical Cox maze procedure by
freezing tissues and causing cellular damage at temperatures of &#x02212;60/&#x02212;70&#x000ba;C with
nitrous oxide supplementation. Despite the advantages of the formation of transmural
lesions and low risk of perforation and thromboembolism, the length of the
application period is a disadvantage.</p><p>In our study, we investigated the maintenance rate of postoperative sinus rhythm and
the factors affecting it in cases involving concomitant AF ablation with mitral
valve surgery and tried to determine whether there is a causal relationship with the
energy source (RFA and CrA) used. We also tried to determine the cumulative effect
of the risk factors on the maintenance of sinus rhythm and their contribution to
appropriate case selection.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Patients</title><p>The study was planned as a retrospective case-control study with the approval of
our institution's ethics committee. The study included 96 patients who underwent
either RFA or CrA procedures concomitant with mitral valve replacement and
tricuspid valve repair between June 2014 and May 2018. The cases were randomly
selected among patients with preoperative AF rhythm at least for three months
(persistent AF) without previous history of ablation and underwent mitral and/or
tricuspid valve surgery, concomitantly with surgical AF ablation. Cases with a
history of such diseases leading to dysrhythmia through electrolyte
irregularities as diabetes mellitus, thyroid and renal dysfunction, and cases of
infective endocarditis requiring complex treatment were excluded. In the study,
information from the hospital patient database and the patient's telephone
records were used. The operations were performed by three different primary
surgeons. All operations were performed under cardiopulmonary bypass. Cases
requiring additional intervention were excluded from the study. The mean age of
the cases was 50.1 (Max-Min = 27-68; 52.1% female). In 89 cases, median
sternotomy was performed whereas right mini-thoracotomy was the approach of
choice in seven cases. Electrocardiogram (ECG) and/or Holter recordings obtained
at follow-up visits performed on the 1<sup>st</sup>, 3<sup>rd</sup>,
6<sup>th</sup> and 15<sup>th</sup> postoperative days and 12<sup>th</sup>
postoperative month by patients following one-week hospitalization were used to
investigate the AF recurrence. A 24-hour Holter monitoring was performed in
cases with a 6-month interval. At the control visits, the presence of acute
inflammation, infection and related complications were evaluated with blood
tests and physical examination (<xref rid="t1" ref-type="table">Table
1</xref>).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographical characteristics of the cases</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="34%" span="1"/><col width="24%" span="1"/><col width="8%" span="1"/><col width="8%" span="1"/><col width="8%" span="1"/><col width="8%" span="1"/><col width="8%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="3">&#x000a0;</th><th align="center" colspan="5" rowspan="1">Ablation type</th></tr><tr><th colspan="2" rowspan="1">RFA (n=54)</th><th colspan="3" rowspan="1">CrA (n=42)</th></tr><tr><th rowspan="1" colspan="1">Mean</th><th rowspan="1" colspan="1">SD</th><th rowspan="1" colspan="1">Mean</th><th rowspan="1" colspan="1">SD</th><th rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="2" rowspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">53</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">0.016<xref ref-type="table-fn" rid="TFN01"><sup>a</sup></xref></td></tr><tr><td align="left" colspan="2" rowspan="1">Left atrium diameter (mm)</td><td align="center" rowspan="1" colspan="1">48.98</td><td align="center" rowspan="1" colspan="1">5.45</td><td align="center" rowspan="1" colspan="1">49.05</td><td align="center" rowspan="1" colspan="1">5.72</td><td align="center" rowspan="1" colspan="1">0.954<xref ref-type="table-fn" rid="TFN01"><sup>a</sup></xref></td></tr><tr><td align="left" colspan="2" rowspan="1">Intensive Care Unit (days)</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">0.145<xref ref-type="table-fn" rid="TFN01"><sup>a</sup></xref></td></tr><tr><td align="left" colspan="2" rowspan="1">Hospitalization (days)</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0.509<xref ref-type="table-fn" rid="TFN01"><sup>a</sup></xref></td></tr><tr><td align="left" colspan="2" rowspan="1">Aortic cross-clamping time (min)</td><td align="center" rowspan="1" colspan="1">63</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">0.035<xref ref-type="table-fn" rid="TFN01"><sup>a</sup></xref></td></tr><tr><td align="left" colspan="2" rowspan="1">Total cardiopulmonary bypass time
(min)</td><td align="center" rowspan="1" colspan="1">66</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">83</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN01"><sup>a</sup></xref></td></tr><tr><td align="left" colspan="2" rowspan="1">Left ventricular ejection fraction
(%)</td><td align="center" rowspan="1" colspan="1">48.78</td><td align="center" rowspan="1" colspan="1">6.52</td><td align="center" rowspan="1" colspan="1">50.07</td><td align="center" rowspan="1" colspan="1">6.13</td><td align="center" rowspan="1" colspan="1">0.325<xref ref-type="table-fn" rid="TFN01"><sup>a</sup></xref></td></tr><tr><td align="left" colspan="2" rowspan="1">Preoperative CRP (mg/dL)</td><td align="center" rowspan="1" colspan="1">4.6</td><td align="center" rowspan="1" colspan="1">1.6</td><td align="center" rowspan="1" colspan="1">4.5</td><td align="center" rowspan="1" colspan="1">1.5</td><td align="center" rowspan="1" colspan="1">0.864<xref ref-type="table-fn" rid="TFN01"><sup>a</sup></xref></td></tr><tr><td align="left" colspan="2" rowspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1"><bold>n</bold></td><td align="center" rowspan="1" colspan="1"><bold>%</bold></td><td align="center" rowspan="1" colspan="1"><bold>n</bold></td><td align="center" rowspan="1" colspan="1"><bold>%</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="4" colspan="1">Body mass index (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">&#x0003c;25</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">54.3</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">45.7</td><td align="center" rowspan="4" colspan="1">0.395<xref ref-type="table-fn" rid="TFN01"><sup>a</sup></xref></td></tr><tr><td align="center" rowspan="1" colspan="1">25-29</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">55.6</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">44.4</td></tr><tr><td align="center" rowspan="1" colspan="1">30-35</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">54.5</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">45.5</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x0003e;35</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="2" colspan="1">Gender</td><td align="center" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="2" colspan="1">0.089<xref ref-type="table-fn" rid="TFN02"><sup>b</sup></xref></td></tr><tr><td align="center" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">65.2</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">34.8</td></tr><tr><td align="left" rowspan="2" colspan="1">Surgical procedure</td><td align="center" rowspan="1" colspan="1">MVR</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">65.9</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">34.1</td><td align="center" rowspan="2" colspan="1">0.079<xref ref-type="table-fn" rid="TFN02"><sup>b</sup></xref></td></tr><tr><td align="center" rowspan="1" colspan="1">MVR+TDVGA</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">48.1</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">51.9</td></tr><tr><td align="left" rowspan="2" colspan="1">Previous stroke</td><td align="center" rowspan="1" colspan="1">Unavailable</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">55.9</td><td align="center" rowspan="1" colspan="1">41</td><td align="center" rowspan="1" colspan="1">44.1</td><td align="center" rowspan="2" colspan="1">0.712<xref ref-type="table-fn" rid="TFN02"><sup>b</sup></xref></td></tr><tr><td align="center" rowspan="1" colspan="1">Available</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">66.7</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">33.3</td></tr><tr><td align="left" rowspan="2" colspan="1">Postoperative pacemaker</td><td align="center" rowspan="1" colspan="1">Unavailable</td><td align="center" rowspan="1" colspan="1">53</td><td align="center" rowspan="1" colspan="1">55.8</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">44.2</td><td align="center" rowspan="2" colspan="1">0.375<xref ref-type="table-fn" rid="TFN02"><sup>b</sup></xref></td></tr><tr><td align="center" rowspan="1" colspan="1">Available</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="2" colspan="1">Chronic obstructive pulmonary
disease</td><td align="center" rowspan="1" colspan="1">Unavailable</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">54.7</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">45.3</td><td align="center" rowspan="2" colspan="1">0.356<xref ref-type="table-fn" rid="TFN02"><sup>b</sup></xref></td></tr><tr><td align="center" rowspan="1" colspan="1">Available</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">70</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">30</td></tr><tr><td align="left" rowspan="4" colspan="1">New York Heart Association functional
class</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">41.7</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">58.3</td><td align="center" rowspan="4" colspan="1">0.13<xref ref-type="table-fn" rid="TFN01"><sup>a</sup></xref></td></tr><tr><td align="center" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">40</td></tr><tr><td align="center" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">63.6</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">36.4</td></tr><tr><td align="center" rowspan="1" colspan="1">IV</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="2" colspan="1">Hypertension</td><td align="center" rowspan="1" colspan="1">Unavailable</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">55.6</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">44.4</td><td align="center" rowspan="2" colspan="1">0.75<xref ref-type="table-fn" rid="TFN02"><sup>b</sup></xref></td></tr><tr><td align="center" rowspan="1" colspan="1">Available</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">40</td></tr></tbody></table><table-wrap-foot><fn id="TFN01"><label>a</label><p>=independent t-test;</p></fn><fn id="TFN02"><label>b</label><p>=Chi-square test; Fisher's exact test, continuity correction
test.</p></fn><fn id="TFN03"><p>CrA=cryoablation; MVR+TDVGA=mitral valve replacement+tricuspid De
Vega annuloplasty; RFA=radiofrequency ablation; SD=standard
deviation</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Ablation Method</title><p>Cryothermal energy (AtriCure<sup>&#x000ae;</sup> cryoICE BOX surgical ablation
system, model cryoICE BOX2-230 VAC) was used as an energy source for ablation in
42 (43.8%) patients, while bipolar radiofrequency energy was used in 54 (56.3%)
patients (AtriCure<sup>&#x000ae;</sup> Articulating Jaw, Isolator Synergy
Access<sup>&#x000ae;</sup>). In all cases, the biatrial ablation technique
shown in <xref ref-type="fig" rid="f1">Figure 1</xref> was applied. Access to
atrioventricular valves and/or atria done through superior septal incision in
the cases with median sternotomy, while in those with the thoracotomy was
performed through the separate left and right atriotomies. Because of the ease
of manipulation, CrA was preferred in cases of thoracotomy. Ablation procedure
was performed based on the incision lines described in <xref ref-type="fig" rid="f1">Figure 1</xref>. The same procedure was preferred for both
cryothermal and radiofrequency ablation. Ablation was performed prior to valve
replacement and division of the left atrial appendage. The left atrial appendix
was closed using 4.0 Prolene sutures. Ablation procedure took 10-15 min for RFA
and 25-30 min for CrA.</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Schematic drawing on ablation technique used in the study.</p></caption><graphic xlink:href="rbccv-33-06-0542-g01"/></fig>
</p></sec><sec><title>Follow-up Protocol</title><p>In the first 3 postoperative days, all cases were followed by continuous ECG
monitoring. Perioperative amiodarone hydrochloride infusion (intravenous in 5%
dextrose, 10-15 mg/kg/24h) was started according to the protocol applied in our
clinic. Treatment with amiodarone hydrochloride (200 mg twice a day
postoperative) and indomethacin (25 mg twice a day p.o.) was continued for 3
months in patients with oral intake. Three months later, metoprolol tartrate
therapy (100 mg once a day postoperative) was started. During an average of 7
days of hospitalization, the heart rate was followed by daily ECG recording.
Patients were called for control visits on the 1<sup>st</sup>, 3<sup>rd</sup>,
6<sup>th</sup> and 15<sup>th</sup> postoperative days and 12 months after
discharge. The patients were examined in terms of inflammation, infection,
stroke and rhythm disturbances, as well as the need for further treatment.
Rhythm follow-up was done with ECG recording in the routine with Holter
monitoring in the 6<sup>th</sup> and 12<sup>th</sup> months. In cases with
permanent pacemaker insertion due to complete atrioventricular block developed
postoperatively, pacemaker follow-up was performed. Antiarrhythmic therapy of
patients with a heart rate below 60 beats/min was discontinued. In patients with
recurrent AF, antiarrhythmic therapy was restarted and 24-hour ECG monitoring
was performed. Electrical cardioversion was applied to cases detected early.
Patients who did not respond to maximal antiarrhythmic treatment and electrical
cardioversion were referred to cardiology for catheter ablation</p></sec><sec><title>Statistical Analysis</title><p>Statistical Package for Social Sciences Statistical Software version 18.0 (SPSS
Inc., Chicago, Il, USA) was used in our single-center retrospective case-control
study. Continuous variables were expressed as mean and standard deviation, while
Student t-test was used for the comparisons. Paired samples t-test was used in
the analysis of the dependent data. Categorical and nominal variables were
expressed in terms of number and percentage (%). The relationship status was
determined by chi-square, Fisher's exact test, and continuity correction tests.
Multinomial logistic and linear regression analyzes were used to determine the
factors affecting maintenance of sinus rhythm by analyzing age, gender, left
ventricular ejection fraction (LVEF), the presence of chronic obstructive
pulmonary disease (COPD), type of energy source, length of hospital stay, body
mass index (BMI), left atrial diameter, cross-clamping time and C-reactive
protein (CRP) levels. The cut-off points of risk factors detected in cases with
postoperative AF recurrence were determined by receiver operating characteristic
(ROC) analysis. The cumulative effect of AF at one year and the significance
level by months were tested by Kaplan-Meier survey analysis. The results were
considered significant when the two-sided <italic>P</italic>-value was
&#x0003c;0.05.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>Bipolar RFA was used in 54 patients (56.3%, 24 females) while CrA was used in 42
patients (43.8%, 26 females). There were no significant differences between the
demographic characteristics of the groups, except age and cross-clamping time.
Distribution of demographic and operative characteristics is shown in <xref rid="t1" ref-type="table">Table 1</xref>. Maintenance rates of sinus rhythm in
the CrA and RFA groups were 97.6% and 96.3% in the early postoperative period, and
88.1% and 83.3% in the 12<sup>th</sup> postoperative month (mean 85.4%),
respectively. No significant difference was found between the groups in relation to
the energy source used in the early postoperative period and after 12 months
(Mentel-Cox <italic>P</italic>=0.455; <xref ref-type="fig" rid="f2">Figure
2</xref>). There was no mortality during follow-up. In the CrA group, postoperative
transient cerebral ischemic attack was observed in one (2.3%) case. In the bipolar
RFA group, perioperative posterior wall rupture was observed in one (1.8%) case,
hemiplegia in one (1.8%) case and permanent pacemaker need in one (1.8%) case. The
wall rupture was sutured without additional complications.</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Survival analysis of cases according to the energy source used. AF=atrial
fibrillation; CrA=cryothermal ablation; RFA=radiofrequency ablation</p></caption><graphic xlink:href="rbccv-33-06-0542-g02"/></fig>
</p><p>In the postoperative follow-up, the causal relationship between AF recurrence and
left atrial diameter, CRP level, hypertension, LVEF, COPD and BMI was found (<xref rid="t2" ref-type="table">Table 2</xref>; <xref ref-type="fig" rid="f3">Figures
3</xref>-<xref ref-type="fig" rid="f6">6</xref>;
<italic>P</italic>&#x0003c;0.05).</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Distribution of risk parameters in relation to postoperative atrial
fibrillation status.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="34%" span="1"/><col width="25%" span="1"/><col width="8%" span="1"/><col width="8%" span="1"/><col width="8%" span="1"/><col width="8%" span="1"/><col width="8%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="3">&#x000a0;</th><th align="center" colspan="5" rowspan="1">AF status</th></tr><tr><th colspan="2" rowspan="1">Unavailable</th><th colspan="2" rowspan="1">Available</th><th rowspan="2" colspan="1"><italic>P</italic>-value</th></tr><tr><th rowspan="1" colspan="1">Mean</th><th rowspan="1" colspan="1">SD</th><th rowspan="1" colspan="1">Mean</th><th rowspan="1" colspan="1">SD</th></tr></thead><tbody><tr><td align="left" colspan="2" rowspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">0.921<xref ref-type="table-fn" rid="TFN04"><sup>a</sup></xref></td></tr><tr><td align="left" colspan="2" rowspan="1">Left atrium diameter (mm)</td><td align="center" rowspan="1" colspan="1">48.1</td><td align="center" rowspan="1" colspan="1">5.11</td><td align="center" rowspan="1" colspan="1">54.36</td><td align="center" rowspan="1" colspan="1">5.06</td><td align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN04"><sup>a</sup></xref></td></tr><tr><td align="left" colspan="2" rowspan="1">Intensive Care Unit (days)</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0.685<xref ref-type="table-fn" rid="TFN04"><sup>a</sup></xref></td></tr><tr><td align="left" colspan="2" rowspan="1">Hospitalization (days)</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0.843<xref ref-type="table-fn" rid="TFN04"><sup>a</sup></xref></td></tr><tr><td align="left" colspan="2" rowspan="1">Aortic cross-clamping time (min)</td><td align="center" rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">0.236<xref ref-type="table-fn" rid="TFN04"><sup>a</sup></xref></td></tr><tr><td align="left" colspan="2" rowspan="1">Cardiopulmonary bypass time (min)</td><td align="center" rowspan="1" colspan="1">75</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">0.08<xref ref-type="table-fn" rid="TFN04"><sup>a</sup></xref></td></tr><tr><td align="left" colspan="2" rowspan="1">Left ventricular ejection fraction (%)</td><td align="center" rowspan="1" colspan="1">50.44</td><td align="center" rowspan="1" colspan="1">5.85</td><td align="center" rowspan="1" colspan="1">42.93</td><td align="center" rowspan="1" colspan="1">5.46</td><td align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN04"><sup>a</sup></xref></td></tr><tr><td align="left" colspan="2" rowspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1"><bold>n</bold></td><td align="center" rowspan="1" colspan="1"><bold>%</bold></td><td align="center" rowspan="1" colspan="1"><bold>n</bold></td><td align="center" rowspan="1" colspan="1"><bold>%</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="4" colspan="1">Body mass index (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">&#x0003c;25</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="4" colspan="1">0.001<xref ref-type="table-fn" rid="TFN04"><sup>a</sup></xref></td></tr><tr><td align="center" rowspan="1" colspan="1">25-29</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">75</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">25</td></tr><tr><td align="center" rowspan="1" colspan="1">30-35</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">81.8</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">18.2</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x0003e;35</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">100</td></tr><tr><td align="left" rowspan="2" colspan="1">Gender</td><td align="center" rowspan="1" colspan="1">Woman</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">86</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="2" colspan="1">0.872<xref ref-type="table-fn" rid="TFN05"><sup>b</sup></xref></td></tr><tr><td align="center" rowspan="1" colspan="1">Man</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">84.8</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">15.2</td></tr><tr><td align="left" rowspan="2" colspan="1">Surgical procedure</td><td align="center" rowspan="1" colspan="1">MVR</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">79.5</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">20.5</td><td align="center" rowspan="2" colspan="1">0.137<xref ref-type="table-fn" rid="TFN05"><sup>b</sup></xref></td></tr><tr><td align="center" rowspan="1" colspan="1">MVR+TDVGA</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">90.4</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">9.6</td></tr><tr><td align="left" rowspan="2" colspan="1">Previous stroke</td><td align="center" rowspan="1" colspan="1">Unavailable</td><td align="center" rowspan="1" colspan="1">79</td><td align="center" rowspan="1" colspan="1">84.9</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">15.1</td><td align="center" rowspan="2" colspan="1">0.472<xref ref-type="table-fn" rid="TFN05"><sup>b</sup></xref></td></tr><tr><td align="center" rowspan="1" colspan="1">Available</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="2" colspan="1">Postoperative pacemaker</td><td align="center" rowspan="1" colspan="1">Unavailable</td><td align="center" rowspan="1" colspan="1">81</td><td align="center" rowspan="1" colspan="1">85.3</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">14.7</td><td align="center" rowspan="2" colspan="1">0.682<xref ref-type="table-fn" rid="TFN05"><sup>b</sup></xref></td></tr><tr><td align="center" rowspan="1" colspan="1">Available</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="2" colspan="1">Chronic obstructive pulmonary disease</td><td align="center" rowspan="1" colspan="1">Unavailable</td><td align="center" rowspan="1" colspan="1">76</td><td align="center" rowspan="1" colspan="1">88.4</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">11.6</td><td align="center" rowspan="2" colspan="1">0.016<xref ref-type="table-fn" rid="TFN05"><sup>b</sup></xref></td></tr><tr><td align="center" rowspan="1" colspan="1">Available</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">40</td></tr><tr><td align="left" rowspan="4" colspan="1">New York Heart Association functional
class</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">95.8</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">4.2</td><td align="center" rowspan="4" colspan="1">0.343<xref ref-type="table-fn" rid="TFN04"><sup>a</sup></xref></td></tr><tr><td align="center" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">20</td></tr><tr><td align="center" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">86.4</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">13.6</td></tr><tr><td align="center" rowspan="1" colspan="1">IV</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="2" colspan="1">Hypertension</td><td align="center" rowspan="1" colspan="1">Unavailable</td><td align="center" rowspan="1" colspan="1">74</td><td align="center" rowspan="1" colspan="1">91.4</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">8.6</td><td align="center" rowspan="2" colspan="1">0.001<xref ref-type="table-fn" rid="TFN05"><sup>b</sup></xref></td></tr><tr><td align="center" rowspan="1" colspan="1">Available</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">53.3</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">46.7</td></tr><tr><td align="left" rowspan="2" colspan="1">Ablation type</td><td align="center" rowspan="1" colspan="1">RFA</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">83.3</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">16.7</td><td align="center" rowspan="2" colspan="1">0.517<xref ref-type="table-fn" rid="TFN05"><sup>b</sup></xref></td></tr><tr><td align="center" rowspan="1" colspan="1">CrA</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">88.1</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">11.9</td></tr><tr><td align="left" rowspan="3" colspan="1">CRP<xref ref-type="table-fn" rid="TFN05"><sup>1</sup></xref> (mg/dL)</td><td align="center" rowspan="1" colspan="1">Postoperative</td><td align="center" rowspan="1" colspan="1">65.2</td><td align="center" rowspan="1" colspan="1">26.4</td><td align="center" rowspan="1" colspan="1">84.5</td><td align="center" rowspan="1" colspan="1">7.5</td><td align="center" rowspan="1" colspan="1">0.266<xref ref-type="table-fn" rid="TFN04"><sup>a</sup></xref></td></tr><tr><td align="center" rowspan="1" colspan="1">15<sup>th</sup> postoperative day&#x000a0;</td><td align="center" rowspan="1" colspan="1">9.3</td><td align="center" rowspan="1" colspan="1">6.9</td><td align="center" rowspan="1" colspan="1">16.4</td><td align="center" rowspan="1" colspan="1">8.9</td><td align="center" rowspan="1" colspan="1">0.003<xref ref-type="table-fn" rid="TFN04"><sup>a</sup></xref></td></tr><tr><td align="center" rowspan="1" colspan="1">1<sup>st</sup> postoperative month</td><td align="center" rowspan="1" colspan="1">2.7</td><td align="center" rowspan="1" colspan="1">1.2</td><td align="center" rowspan="1" colspan="1">5.1</td><td align="center" rowspan="1" colspan="1">1.0</td><td align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN04"><sup>a</sup></xref></td></tr></tbody></table><table-wrap-foot><fn id="TFN04"><label>a</label><p>=independent t test;</p></fn><fn id="TFN05"><label>b</label><p>=Chi-square, Fisher's exact test, continuity correction test</p></fn><fn id="TFN06"><label>1</label><p>=for statistical analysis of AF recurrence, the data on the same day and
month were taken into consideration.</p></fn><fn id="TFN07"><p>MVR+TDVGA=mitral valve replacement +tricuspid De Vega annuloplasty;
SD=standard deviation; AF=atrial fibrillation; CrA=cryothermal ablation;
CRP=C-reactive protein; MVR=mitral valve replacement; RFA=radiofrequency
ablation</p></fn></table-wrap-foot></table-wrap><p>
<fig id="f3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>a) Change in the recurrence of AF with left atrium diameter and LVEF. b,
c, d) Survival analysis of postoperative COPD, BMI and hypertension with
Mentel-Cox significance values. BMI=body mass index; COPD=chronic
obstructive pulmonary disease; LA= eft atrium; LVEF=left ventricular
ejection fraction</p></caption><graphic xlink:href="rbccv-33-06-0542-g03"/></fig>
</p><p>
<fig id="f6" orientation="portrait" position="float"><label>Fig. 6</label><caption><p>Factors correlated with AF recurrence after ablation (r correlation
coefficient of significance at P&#x0003c;0.05 were taken). AF=atrial
fibrillation; COPD=chronic obstructive pulmonary disease; CRP=C-reactive
protein; LA=left atrium; LVEF=left ventricular ejection fraction</p></caption><graphic xlink:href="rbccv-33-06-0542-g06"/></fig>
</p><p>There was a moderate correlation (37.4%) between left atrial diameter and AF
recurrence (<italic>P</italic>=0.001; r=0.374; <xref ref-type="fig" rid="f3">Figure
3</xref>). Sensitivity and specificity of left atrial diameter with a cut-off
value of 50.5 mm for the maintenance of the sinus rhythm were 85.7% and 70.7%,
respectively (area=0.805; <italic>P</italic>=0.001; 95% CI=0.687-0.923; <xref ref-type="fig" rid="f5">Figure 5</xref>).</p><p>
<fig id="f5" orientation="portrait" position="float"><label>Fig. 5</label><caption><p>ROC curve analysis graphs of factors affecting AF recurrence. AF=atrial
fibrillation; BMI=body mass index; LA=left atrium; LVEF=left ventricular
ejection fraction</p></caption><graphic xlink:href="rbccv-33-06-0542-g05"/></fig>
</p><p>The mean preoperative CRP value was 4.5 mg/dL. There was a moderate positive
correlation between AF recurrence and CRP level on the 15<sup>th</sup> postoperative
day and at the 1<sup>st</sup> postoperative month (<italic>P</italic>=0.001; r=0.321
and <italic>P</italic>=0.001; r=0.324, respectively; <xref ref-type="fig" rid="f3">Figure 3D</xref>), whereas no correlation was found between AF recurrence and
CRP on the 1<sup>st</sup> postoperative day (<italic>P</italic>=0.193; r=0.134). In
the ROC analysis, the CRP level on the 15<sup>th</sup> postoperative day with a
cut-off value of 12 mg/dL showed sensitivity of 83.3% and specificity of 88.9%
(area=0.873; <italic>P</italic>=0.002; 98% CI=0.804-0.942). Sensitivity and
specificity of CRP level at a cut-off value of 4.5 mg/dL for the maintenance of the
sinus rhythm at 1<sup>st</sup> postoperative month were 66.7% and 87.8%,
respectively (area=0.879; <italic>P</italic>=0.046, 95% CI = 0.789-0.968; <xref rid="t1" ref-type="table">Table 1</xref>; <xref ref-type="fig" rid="f5">Figure
5</xref>).</p><p>As BMI values increased, the AF recurrence rate increased significantly. The increase
in BMI affected AF recurrence by 3.2 times (<italic>P</italic>=0.001; r=0.442; <xref ref-type="fig" rid="f3">Figures 3</xref> and <xref ref-type="fig" rid="f5">5</xref>). In cases with BMI&#x0003e;30 kg/m<sup>2</sup> (14.6%; 14 cases),
recurrent AF frequency (35.7%; 5 cases) was significant (<xref rid="t2" ref-type="table">Table 2</xref>). In the ROC analysis, the sensitivity of the BMI at 30
kg/m<sup>2</sup> cut-off was 35.7%, while the specificity was 89% (area=0.816;
<italic>P</italic>=0.001; 95% CI=0.720-0.911).</p><p>The mean value of LVEF was 49.3% (35-60%). As LVEF decreased, AF recurrence increased
(40.1%), indicating a moderate inverse correlation (<italic>P</italic>=0.001;
r=&#x02212;0.401). Sensitivity at 37.5% cut-off value of LVEF in ROC analysis was 96.3%,
while the specificity was 11.4% (area=0.825; <italic>P</italic>=0.001; 95%
CI=0.711-0.939; <xref ref-type="fig" rid="f3">Figures 3</xref> and <xref ref-type="fig" rid="f5">5</xref>).</p><p>It was found that 15.7% of all cases had hypertension. Considering the prevalence of
hypertension in patients with AF (50%), this ratio was nonspecific in our study,
which included only valvular patients. AF recurrence was seen in 7 of 15 (46.7%)
hypertensive patients. Hypertension affected postoperative AF recurrence by 5.3
times (<italic>P</italic>=0.001; r=0.391; <xref ref-type="fig" rid="f4">Figure
4</xref>; OR=0.192; 96% CI=0.084-0.453). Patients with COPD accounted for 10.4%
of our cases. Recurrent AF was observed in 4 (40%) cases with COPD. Low correlation
with AF recurrence was detected (<italic>P</italic>=0.016; r=0.246; <xref ref-type="fig" rid="f5">Figure 5</xref>).</p><p>
<fig id="f4" orientation="portrait" position="float"><label>Fig. 4</label><caption><p>The change in CRP levels in relation to the cases with and without AF
recurrence and the significance ratios according to Cox regression
analysis. CRP=C-reactive protein</p></caption><graphic xlink:href="rbccv-33-06-0542-g04"/></fig>
</p><p>Postoperative intensive antiarrhythmic therapy was initiated in all cases and
continued for 3 months. Electrical cardioversion was applied in 3 (3.1%) cases in
one year. Additional catheter ablation was performed for 2 (14%) of 14 (14.1%)
patients who developed AF at annual follow-up. No mortality was observed.</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>From 1987 to 1992, when the Cox maze procedure was reported for the first time,
continuity of sinus rhythm was reported to be 85-98% in the Cox maze III procedure,
which was developed through experiments with dog models<sup>[</sup><sup><xref rid="r7" ref-type="bibr">7</xref></sup><sup>]</sup>. In a meta-analysis
involving six studies, the maintenance rate of sinus rhythm in a one-year follow-up
of 97 cases undergoing mitral valve replacement was reported as being 44% for those
undergoing concomitant RFA and 4.5% for those without RFA<sup>[</sup><sup><xref rid="r8" ref-type="bibr">8</xref></sup><sup>]</sup>. In a meta-analysis
involving randomized and non-randomized controlled trials, Barnett and
Ad<sup>[</sup><sup><xref rid="r9" ref-type="bibr">9</xref></sup><sup>]</sup>
reported higher rates of sinus rhythm restoration (94%) in patients undergoing AF
ablation in addition to cardiac surgery than in those patients undergoing cardiac
surgery alone (4.4%). The limiting characteristic of the original cut-and-sew
technique was the fear of surgeons arising from the complexity of the procedure, as
well as the increased possibility of complete atrioventricular block and other
complications. For this reason, the Cox maze IV procedure, which produces transmural
lesions with different energy sources, was developed. In a study by Lall et
al.<sup>[</sup><sup><xref rid="r10" ref-type="bibr">10</xref></sup><sup>]</sup>,
maintenance rates of sinus rhythm for one year follow-up after Cox maze III and IV
procedures were found to be 96% and 93%, respectively. The success rate of
concomitantly performed AF ablations was 67-84% in retrospective
reports<sup>[</sup><sup><xref rid="r11" ref-type="bibr">11</xref></sup><sup>]</sup>. The variation in the studies was due to different
lesion lines, different sources of energy, surgeon experience and follow-up
strategies. In our study, the maintenance rate of sinus rhythm was 85.4% at one-year
follow-up. Our results were similar to those of the literature. It is understood
from the studies performed by McCarthy et al.<sup>[</sup><sup><xref rid="r12" ref-type="bibr">12</xref></sup><sup>]</sup> that there are significant differences
in quality of life among patients with AF who underwent simultaneous AF ablation
with valve replacement compared with patients who had valve replacement without AF
ablation.</p><p>Bipolar RFA and CrA are the most frequently recommended techniques for ablation
during mitral valve replacement<sup>[</sup><sup><xref rid="r13" ref-type="bibr">13</xref>,<xref rid="r14" ref-type="bibr">14</xref></sup><sup>]</sup>. Bipolar RFA works according to the principle of
lesion formation through a transmural hyperthermic heat exchanger clamp in
endocardial and epicardial tissues. Feedback information on whether these lesions
were transmural or not was effective in the transition from unipolar to bipolar
systems. Bipolar RFA devices have been used in our hospital since 2007, but after
2014, nitrous oxide-based CrA devices were preferred. Cryotherapy works through the
Joule-Thomson effect, cooling the tissues. The intracellular ice formation, which
can be monitored intraoperatively, results in necrosis of the
cell<sup>[</sup><sup><xref rid="r13" ref-type="bibr">13</xref></sup><sup>]</sup>. Transmural lesion with CrA was demonstrated
histologically in experimental sheep models in endocardial and epicardial
applications<sup>[</sup><sup><xref rid="r14" ref-type="bibr">14</xref></sup><sup>]</sup>. It has advantages such as visual confirmation of
ice formation, formation of progressive transmural lesions, low risk of injury to
neighboring tissues and no reports of injuries in the valve leaflet, phrenic nerve
and coronary arteries provided in the literature, even though it is relatively
early. The length of the application is the disadvantage of CrA, which has been
shown to have no effect on morbidity and mortality<sup>[</sup><sup><xref rid="r15" ref-type="bibr">15</xref></sup><sup>]</sup>. Brick et
al.<sup>[</sup><sup><xref rid="r15" ref-type="bibr">15</xref></sup><sup>]</sup>
reported in their meta-analysis of 19 articles that found no difference between the
one year success rates of sinus rhythm maintaining after RFA (67-96%) and CrA
(65.5-97.7%). In concomitant interventions, the maintenance rate of one year sinus
rhythm was 83.3% for bipolar RFA and 88.1% for CrA (<xref ref-type="fig" rid="f2">Figure 2</xref>). However, the effect of energy sources on AF recurrence was
not significant.</p><p>Although Cox maze IV procedure is applicable in both atriums, there are publications
in recent years reporting that only left atrial ablation could have been
sufficient<sup>[</sup><sup><xref rid="r16" ref-type="bibr">16</xref></sup><sup>]</sup>. In a study by Gillinov et
al.<sup>[</sup><sup><xref rid="r17" ref-type="bibr">17</xref></sup><sup>]</sup> comparing biatrial AF ablation with left atrial AF
ablation, the biatrial ablation technique was significantly superior to the other.
However, in the studies of Worku et al.<sup>[</sup><sup><xref rid="r18" ref-type="bibr">18</xref></sup><sup>]</sup>, the rate of persistent pacemaker
implantation after biatrial AF ablation was reported as significantly higher. In 268
cases of biatrial cryothermal Cox maze IV procedure performed by Funatsu et
al.<sup>[</sup><sup><xref rid="r19" ref-type="bibr">19</xref></sup><sup>]</sup>,
the rate of sinus rhythm restoration in permanent AF was reported to be 80.2%, while
the need for permanent pacemaker was 8.3%. The need for permanent pacemaker can be
explained by the preoperative undetected sinus node dysfunction of patients with AF.
The incidence of pacemaker implantation is also high in the routine follow-up of
these cases<sup>[</sup><sup><xref rid="r20" ref-type="bibr">20</xref></sup><sup>]</sup>. The fact is that surgical ablation performed only
in the left atrium may be satisfactory, but the increase in flatter incidence from
the right atrium after surgery is inevitable. For this reason, biatrial ablation
should be preferred, especially in cases with a history of the atrial
flutter<sup>[</sup><sup><xref rid="r19" ref-type="bibr">19</xref></sup><sup>]</sup>. Permanent pacemaker requirement was seen in only
one (1.8%) of our patients who underwent RFA. Our rate of sinus rhythm per year was
similar to that of the literature. Our opinion is that it is correct for the surgeon
to make a case-based decision on the method of ablation.</p><p>Bipolar RFA is not used in minimally invasive procedures because of the difficulties
encountered in the complete realization of Cox's maze lesions and its ability to
allow only the pulmonary vein isolation, which we refer to as "box lesions".
However, CrA is more advantageous in minimally invasive procedures, since the tip of
the catheter used can be put in any desired shape.</p><p>Analyzes have shown that ablation does not increase operative mortality, and, on the
contrary, reduces late mortality and morbidity since it reduces postoperative
thromboembolic risk<sup>[</sup><sup><xref rid="r15" ref-type="bibr">15</xref></sup><sup>]</sup>. Phan et al.<sup>[</sup><sup><xref rid="r20" ref-type="bibr">20</xref></sup><sup>]</sup> found no significant difference in
postoperative stroke and mortality between two groups of patients, one with
concomitant AF ablation and the other without it. There was no mortality in our
study. One (1.8%) case had a stroke in the late period. Gillinov et
al.<sup>[</sup><sup><xref rid="r17" ref-type="bibr">17</xref></sup><sup>]</sup> reported 3% incidence of stroke for one-year
follow-up. Our stroke rate was much lower than the risk of AF induced
thromboembolism (10-20%), even if the risk of valve thrombosis was added. Despite
the prolonged duration of cardiopulmonary bypass, there was no difference in terms
of stroke and mortality in the CrA group.</p><p>Complications such as esophageal and coronary arterial damage that occurred in the
first applications are gradually reduced with the introduction of new energy
sources<sup>[</sup><sup><xref rid="r21" ref-type="bibr">21</xref></sup><sup>]</sup>. In a published report of esophageal perforations
after surgical AF ablation, 26 of 29 cases of esophageal perforation were reported
to have occurred after RFA and one case after CrA<sup>[</sup><sup><xref rid="r21" ref-type="bibr">21</xref></sup><sup>]</sup>. No esophageal
perforation was detected in our cases. In only one case, there was minimal damage to
the posterior wall of the left atrium after bipolar RFA. The damage was repaired
without additional complications.</p><p>It is not sufficient to use only intermittent ECG records in the long-term follow-up
of patients with restored sinus rhythm due of the possibility that rhythm is caught
in a short and transient period of sinus node activity, and thus, a paroxysmal
atrial arrhythmia may go unnoticed. For this reason, we think that it is best to use
a 24-hour Holter ECG or rhythm monitor, especially in the early period. In our
cases, we performed Holter monitoring every 6 months. Continuous ECG monitoring was
performed in cases with recurrent AF. Therapeutic modalities such as antiarrhythmic
therapy and cardioversion were applied in the recurrent AF cases detected at 12
months of follow-up.</p><p>After the operation, amiodarone and nonsteroidal anti-inflammatory drug therapy were
applied for 3 months, considering the catecholamine increase and metabolic inducers.
The first 3 months after ablation are called the "blind period". In this period,
antiarrhythmics may prevent early AF recurrence triggered by ablated tissue-derived
rhythm disorders (proarrhythmias)<sup>[</sup><sup><xref rid="r22" ref-type="bibr">22</xref></sup><sup>]</sup>. Amiodarone also provides rate control against
arrhythmia.</p><p>Restoration of sinus rhythm after ablation is an independent predictor of successful
ablation in the 12<sup>th</sup> postoperative month. Damiano et
al.<sup>[</sup><sup><xref rid="r23" ref-type="bibr">23</xref></sup><sup>]</sup> found high rates of AF recurrence at a
12<sup>th</sup> postoperative month in patients with atrial tachycardia in the
early postoperative period. AF recurrence was observed in 6 of 14 (42.9%) cases in
the first 15 days (<xref ref-type="fig" rid="f2">Figure 2</xref>). We think that
early AF recurrence is caused by the intense effect of proarrhythmic factors.</p><p>Since the early 2000's, researchers have argued that AF is caused by inflammatory
processes. The study results have shown that there is a correlation between CRP and
inflammation<sup>[</sup><sup><xref rid="r24" ref-type="bibr">24</xref></sup><sup>]</sup>. However, the effect of inflammation on the left
atrium size and the pathogenesis of the dysrhythmias is controversial. Psychari et
al.<sup>[</sup><sup><xref rid="r24" ref-type="bibr">24</xref></sup><sup>]</sup>
found a significant association between AF occurrence and CRP and interleukin-6
levels in their study of 90 patients. In their study of 50 patients with and without
persistent AF, Watanabe et al.<sup>[</sup><sup><xref rid="r25" ref-type="bibr">25</xref></sup><sup>]</sup> reported that the left ventricular mass and
increased left ventricular end-diastolic diameter were determinants of CRP elevation
and AF persistence. In our study, CRP levels were found to be high but not
significant on the 1<sup>st</sup> postoperative day. On the 15<sup>th</sup>
postoperative day, the sensitivity and specificity of CRP in terms of effect on AF
recurrence with a cut-off value of 12 mg/dL were found to be 83.3% and 88.9%,
respectively (area=0.873; <italic>P</italic>=0.002; 98% CI=0.804-0.942; <xref ref-type="fig" rid="f2">Figures 2</xref>-<xref ref-type="fig" rid="f4">4</xref>). The sensitivity and specificity ratios at 1<sup>st</sup> postoperative
month for CRP with a cut-off value of 4.5 mg/dL were 66.7% and 87.8%, respectively
(area=0.879; P=0.046; 95% CI=0.789-0.968; <xref rid="t1" ref-type="table">Table
1</xref>). The effect of energy sources on postoperative CRP level was not
significant (<italic>P</italic>&#x0003e;0.05; <xref rid="t1" ref-type="table">Table
1</xref>).</p><p>Funatsu et al.<sup>[</sup><sup><xref rid="r19" ref-type="bibr">19</xref></sup><sup>]</sup> reported that AF recurrence rate after ablation was
increased when the left atrium size was &#x02265;70 mm and AF had been present over
10 years. Some studies have reported that left atrium diameter greater than 60 mm
and the presence of hypertension are independent risk factors for unsuccessful
ablation<sup>[</sup><sup><xref rid="r23" ref-type="bibr">23</xref></sup><sup>]</sup>. Although the effect of left atrium diameter on
primary AF is supported, there is insufficient data on whether left atrium diameter
after ablation is a predictor for AF recurrence. In our study, sensitivity and
specificity ratios of left atrium diameter for AF recurrence with a cut-off value of
50.5 mm were 85.7% and 70.7%, respectively. Left atrium diameter was greater than
50.5 mm in 12 (85.7%) of the 14 patients with recurrent AF. Our results are similar
to those of Chavez et al.<sup>[</sup><sup><xref rid="r11" ref-type="bibr">11</xref></sup><sup>]</sup>.</p><p>Ducceschi et al.<sup>[</sup><sup><xref rid="r26" ref-type="bibr">26</xref></sup><sup>]</sup> reported that, in a series of 150 cases (BMI &#x0003e;30
kg/m<sup>2</sup>), AF was more common in obese patients. Adipose tissue is an
active endocrine organ that secretes many hormones and cytokines (TNF-&#x003b1;,
IL-6, IL-8), such as leptin, resistin and adiponectin. These cytokines lead to
systemic inflammation and affect insulin resistance and pulmonary
function<sup>[</sup><sup><xref rid="r24" ref-type="bibr">24</xref></sup><sup>]</sup>. This causes left atrium growth and contributes to
irregularity in electrolyte metabolism. Recurrent AF was more frequent in our cases
with postoperative BMI &#x0003e;30 kg/m<sup>2</sup> (14 cases) and the difference was
significant (<xref rid="t2" ref-type="table">Table 2</xref>; <xref ref-type="fig" rid="f3">Figures 3</xref> to <xref ref-type="fig" rid="f6">6</xref>).
Sensitivity and specificity of obesity were 35.7% and 89%, respectively, in terms of
AF recurrence with a cut-off value of 30 kg m<sup>2</sup> (area=0.816;
<italic>P</italic>=0.001; 95% CI=0.720-0.911). The increase in BMI affected AF
recurrence by 3.2-fold.</p><p>The prevalence of hypertension in developed countries is around
25-30%<sup>[</sup><sup><xref rid="r27" ref-type="bibr">27</xref></sup><sup>]</sup>. Cohort studies showed the presence of hypertension
in 53% of patients with AF and a causal linkage in 15% of patients with
AF<sup>[</sup><sup><xref rid="r27" ref-type="bibr">27</xref></sup><sup>]</sup>.
In our cases, there were sufficient reasons for the development of AF, but 15
patients were being treated for hypertension at the same time (<xref rid="t1" ref-type="table">Table 1</xref>). Recurrence of postoperative AF was
seen in 7 (46.7%) cases with hypertension. The recurrence of AF was 5.3 times more
frequent in hypertensive cases when compared to non-hypertensive cases.</p><p>Our experience and the studies reported in the literature have shown that successful
results are obtained if AF ablation is carried out during cardiac surgery. Although
there are no clear criteria for patient selection, cases with left atrial diameter
&#x02265;50 mm, LVEF &#x02264; 37%, and heart failure of NYHA class III-IV should be
excluded. Nevertheless, in the American College of Cardiology (ACC)/AHA and European
Society of Cardiology (ESC)/EHRA guidelines<sup>[</sup><sup><xref rid="r4" ref-type="bibr">4</xref></sup><sup>]</sup>, AF ablation is recommended with a low
level of evidence (Class 2b) for cases with medical treatment refractory to
symptomatic heart failure and/or atrial enlargement. In our cases, LVEF presented
96.3% sensitivity and 11.4% specificity with a cut-off value of 37.5% (area=0.825;
<italic>P</italic>=0.001; 95% CI 0.711-0.939; <xref ref-type="fig" rid="f3">Figures 3</xref> and <xref ref-type="fig" rid="f5">5</xref>).</p><sec><title>Limitation</title><p>Detection of recurrent AF in a longer period may not be possible, since our
follow-up period has been limited to 1 year. For this reason, we realize that
the most valuable results for the comparison of different energy sources used in
Cox maze IV procedure will come from large series with long-term follow-up.</p><p>In our single-center nonrandomized trial, it was not possible to eliminate the
confounding variables that affect AF recurrence. For this reason, our 1-year
follow-up was influenced by factors other than energy sources. However, it is
understood from the demographic data that the confounding factors that we have
detected do not display nonuniform distribution among the groups (<xref rid="t1" ref-type="table">Table 1</xref>).</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>Considering the high incidence and complication rate, persistent AF requires
aggressive treatment and follow-up, we believe that it is necessary to perform AF
ablation in case of necessity in all cases where cardiac surgery is planned. In our
cases with bipolar RFA and CrA, we found acceptable rates of AF recurrence,
mortality and stroke at one-year follow-up. Even if there is no difference between
the efficiency of the energy systems we used, an increase in the demand for
alternative systems will occur in a world moving toward less invasive procedures. We
believe that controlling risk factors and following appropriate medical procedures
are as effective as surgical procedure and energy source on sinus rhythm
maintenance. However, we believe that if cardiologists and surgeons interested in
electrophysiology work together with a multidisciplinary team approach in choosing
the right patient and procedure, success rate first and then quality of life will
increase.</p><table-wrap id="t4" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1"><bold>Authors&#x02019; roles &#x00026;
responsibilities</bold></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">&#x000dc;V</td><td align="left" rowspan="1" colspan="1">Substantial contributions to the conception or design
of the work; or the acquisition, analysis, or interpretation of data
for the work; drafting the work or revising it critically for
important intellectual content; agreement to be accountable for all
aspects of the work in ensuring that questions related to the
accuracy or integrity of any part of the work are appropriately
investigated and resolved; final approval of the version to be
published</td></tr><tr><td align="left" rowspan="1" colspan="1">AYB</td><td align="left" rowspan="1" colspan="1">Final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">AAA</td><td align="left" rowspan="1" colspan="1">Agreement to be accountable for all aspects of the work
in ensuring that questions related to the accuracy or integrity of
any part of the work are appropriately investigated and resolved;
final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">MK</td><td align="left" rowspan="1" colspan="1">Drafting the work or revising it critically for
important intellectual content; final approval of the version to be
published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at Dr. Siyami Ersek Thoracic and Cardiovascular
Surgery Training and Research Hospital, Istanbul, Turkey.</p></fn><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camm</surname><given-names>AJ</given-names></name><name><surname>Kirchhof</surname><given-names>P</given-names></name><name><surname>Lip</surname><given-names>GY</given-names></name><name><surname>Schotten</surname><given-names>U</given-names></name><name><surname>Savelieva</surname><given-names>I</given-names></name><name><surname>Ernst</surname><given-names>S</given-names></name><etal/><collab>ESC Committee for Practice Guidelines</collab></person-group><article-title>Guidelines for the management of atrial fibrillation: the Task
Force for the Management of Atrial Fibrillation of the European Society of
Cardiology (ESC)</article-title><source>Europace</source><year>2010</year><volume>12</volume><issue>10</issue><fpage>1360</fpage><lpage>1420</lpage><pub-id pub-id-type="pmid">20876603</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fornari</surname><given-names>LS</given-names></name><name><surname>Calderaro</surname><given-names>D</given-names></name><name><surname>Nassar</surname><given-names>IB</given-names></name><name><surname>Lauretti</surname><given-names>C</given-names></name><name><surname>Nakamura</surname><given-names>L</given-names></name><name><surname>Bagnatori</surname><given-names>R</given-names></name><etal/></person-group><article-title>Misuse of antithrombotic therapy in atrial fibrillation patients:
frequent, pervasive and persistent</article-title><source>J Thromb Thrombolysis</source><year>2007</year><volume>23</volume><issue>1</issue><fpage>65</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">17186395</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adalet</surname><given-names>K</given-names></name></person-group><article-title>The surgical treatment of atrial fibrillation</article-title><source>T&#x000fc;rk Kardiyol Dern Arfl</source><year>2002</year><volume>30</volume><fpage>104</fpage><lpage>118</lpage></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calkins</surname><given-names>H</given-names></name><name><surname>Kuck</surname><given-names>KH</given-names></name><name><surname>Cappato</surname><given-names>R</given-names></name><name><surname>Brugada</surname><given-names>J</given-names></name><name><surname>Camm</surname><given-names>AJ</given-names></name><name><surname>Chen</surname><given-names>SA</given-names></name><etal/><collab>Heart Rhythm Society Task Force on Catheter and Surgical Ablation of
Atrial Fibrillation</collab></person-group><article-title>2012 HRS/EHRA/ECAS expert consensus statement on catheter and
surgical ablation of atrial fibrillation: recommendations for patient
selection, procedural techniques, patient management and follow-up,
definitions, endpoints, and research trial design: a report of the Heart
Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial
Fibrillation. Developed in partnership with the European Heart Rhythm
Association (EHRA), a registered branch of the European Society of
Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in
collaboration with the American College of Cardiology (ACC), American Heart
Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the
Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the
American College of Cardiology Foundation, the American Heart Association,
the European Cardiac Arrhythmia Society, the European Heart Rhythm
Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm
Society, and the Heart Rhythm Society</article-title><source>Heart Rhythm</source><year>2012</year><volume>9</volume><issue>4</issue><fpage>632</fpage><lpage>696</lpage><pub-id pub-id-type="pmid">22386883</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gammie</surname><given-names>JS</given-names></name><name><surname>Haddad</surname><given-names>M</given-names></name><name><surname>Milford-Beland</surname><given-names>S</given-names></name><name><surname>Welke</surname><given-names>KF</given-names></name><name><surname>Ferguson Jr</surname><given-names>TB</given-names></name><name><surname>O'Brien</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Atrial fibrillation correction surgery: lessons from the Society
of Thoracic Surgeons National Cardiac Database</article-title><source>Ann Thorac Surg</source><year>2008</year><volume>85</volume><issue>3</issue><fpage>909</fpage><lpage>914</lpage><pub-id pub-id-type="pmid">18291169</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillinov</surname><given-names>AM</given-names></name><name><surname>Sirak</surname><given-names>J</given-names></name><name><surname>Blackstone</surname><given-names>EH</given-names></name><name><surname>McCarthy</surname><given-names>PM</given-names></name><name><surname>Rajeswaran</surname><given-names>J</given-names></name><name><surname>Pettersson</surname><given-names>G</given-names></name><etal/></person-group><article-title>The Cox maze procedure in mitral valve disease: predictors of
recurrent atrial fibrillation</article-title><source>J Thorac Cardiovasc Surg</source><year>2005</year><volume>130</volume><issue>6</issue><fpage>1653</fpage><lpage>1660</lpage><pub-id pub-id-type="pmid">16308012</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>JL</given-names></name><name><surname>Ad</surname><given-names>N</given-names></name><name><surname>Palazzo</surname><given-names>T</given-names></name><name><surname>Fitzpatrick</surname><given-names>S</given-names></name><name><surname>Suyderhoud</surname><given-names>JP</given-names></name><name><surname>DeGroot</surname><given-names>KW</given-names></name><etal/></person-group><article-title>Current status of the Maze procedure for the treatment of atrial
fibrillation</article-title><source>Semin Thorac Cardiovasc Surg</source><year>2000</year><volume>12</volume><issue>1</issue><fpage>15</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">10746917</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doukas</surname><given-names>G</given-names></name><name><surname>Samani</surname><given-names>NJ</given-names></name><name><surname>Alexiou</surname><given-names>C</given-names></name><name><surname>Oc</surname><given-names>M</given-names></name><name><surname>Chin</surname><given-names>DT</given-names></name><name><surname>Stafford</surname><given-names>PG</given-names></name><etal/></person-group><article-title>Left atrial radiofrequency ablation during mitral valve surgery
for continuous atrial fibrillation: a randomized controlled
trial</article-title><source>JAMA</source><year>2005</year><volume>294</volume><issue>18</issue><fpage>2323</fpage><lpage>2329</lpage><pub-id pub-id-type="pmid">16278360</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnett</surname><given-names>SD</given-names></name><name><surname>Ad</surname><given-names>N</given-names></name></person-group><article-title>Surgical ablation as treatment for the elimination of atrial
fibrillation: a meta-analysis</article-title><source>J Thorac Cardiovasc Surg</source><year>2006</year><volume>131</volume><issue>5</issue><fpage>1029</fpage><lpage>1035</lpage><pub-id pub-id-type="pmid">16678586</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lall</surname><given-names>SC</given-names></name><name><surname>Melby</surname><given-names>SJ</given-names></name><name><surname>Voeller</surname><given-names>RK</given-names></name><name><surname>Zierer</surname><given-names>A</given-names></name><name><surname>Bailey</surname><given-names>MS</given-names></name><name><surname>Guthrie</surname><given-names>TJ</given-names></name><etal/></person-group><article-title>The effect of ablation technology on surgical outcomes after the
Cox-maze procedure: a propensity analysis</article-title><source>J Thorac Cardiovasc Surg</source><year>2007</year><volume>133</volume><issue>2</issue><fpage>389</fpage><lpage>396</lpage><pub-id pub-id-type="pmid">17258570</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chavez</surname><given-names>EK</given-names></name><name><surname>Colafranceschi</surname><given-names>AS</given-names></name><name><surname>Monteiro</surname><given-names>AJO</given-names></name><name><surname>Canale</surname><given-names>SC</given-names></name><name><surname>Mesquita</surname><given-names>ET</given-names></name><name><surname>Weksler</surname><given-names>C</given-names></name><etal/></person-group><article-title>Surgical treatment of atrial fibrillation in patients with
rheumatic valve disease</article-title><source>Braz J Cardiovasc Surg</source><year>2017</year><volume>32</volume><issue>3</issue><fpage>202</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">28832799</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>PM</given-names></name><name><surname>Manjunath</surname><given-names>A</given-names></name><name><surname>Kruse</surname><given-names>J</given-names></name><name><surname>Andrei</surname><given-names>AC</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>McGee Jr</surname><given-names>EC</given-names></name><etal/></person-group><article-title>Should paroxysmal atrial fibrillation be treated during cardiac
surgery?</article-title><source>J Thorac Cardiovasc Surg</source><year>2013</year><volume>146</volume><issue>4</issue><fpage>810</fpage><lpage>823</lpage><pub-id pub-id-type="pmid">23890981</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gage</surname><given-names>AA</given-names></name><name><surname>Baust</surname><given-names>J</given-names></name></person-group><article-title>Mechanism of tissue injury in cryosurgery</article-title><source>Cryobiology</source><year>1998</year><volume>37</volume><issue>3</issue><fpage>171</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">9787063</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallegos</surname><given-names>RP</given-names></name><name><surname>Rivard</surname><given-names>AL</given-names></name><name><surname>Rajab</surname><given-names>TK</given-names></name><name><surname>Schmitto</surname><given-names>JD</given-names></name><name><surname>Lahti</surname><given-names>MT</given-names></name><name><surname>Kirchhof</surname><given-names>N</given-names></name><etal/></person-group><article-title>Transmural atrial fibrosis after epicardial and endocardial
argon-powered CryoMaze ablation</article-title><source>J Card Surg</source><year>2011</year><volume>26</volume><issue>2</issue><fpage>240</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">21395689</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brick</surname><given-names>AV</given-names></name><name><surname>Braile</surname><given-names>DM</given-names></name></person-group><article-title>Surgical ablation of atrial fibrillation using energy
sources</article-title><source>Braz J Cardiovasc Surg</source><year>2015</year><volume>30</volume><issue>6</issue><fpage>636</fpage><lpage>643</lpage><pub-id pub-id-type="pmid">26934404</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khargi</surname><given-names>K</given-names></name><name><surname>Deneke</surname><given-names>T</given-names></name><name><surname>Lemke</surname><given-names>B</given-names></name><name><surname>Laczkovics</surname><given-names>A</given-names></name></person-group><article-title>Irrigated radiofrequency ablation is a safe and effective
technique to treat chronic atrial fibrillation</article-title><source>Interact Cardiovasc Thorac Surg</source><year>2003</year><volume>2</volume><issue>3</issue><fpage>241</fpage><lpage>245</lpage><pub-id pub-id-type="pmid">17670038</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillinov</surname><given-names>AM</given-names></name><name><surname>Gelijns</surname><given-names>AC</given-names></name><name><surname>Parides</surname><given-names>MK</given-names></name><name><surname>DeRose Jr</surname><given-names>JJ</given-names></name><name><surname>Moskowitz</surname><given-names>AJ</given-names></name><name><surname>Voisine</surname><given-names>P</given-names></name><etal/><collab>CTSN Investigators</collab></person-group><article-title>Surgical ablation of atrial fibrillation during mitral-valve
surgery</article-title><source>N Engl J Med</source><year>2015</year><volume>372</volume><issue>15</issue><fpage>1399</fpage><lpage>1409</lpage><pub-id pub-id-type="pmid">25853744</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Worku</surname><given-names>B</given-names></name><name><surname>Pak</surname><given-names>SW</given-names></name><name><surname>Cheema</surname><given-names>F</given-names></name><name><surname>Russo</surname><given-names>M</given-names></name><name><surname>Housman</surname><given-names>B</given-names></name><name><surname>Van Patten</surname><given-names>D</given-names></name><etal/></person-group><article-title>Incidence and predictors of pacemaker placement after surgical
ablation for atrial fibrillation</article-title><source>Ann Thorac Surg</source><year>2011</year><volume>92</volume><issue>6</issue><fpage>2085</fpage><lpage>2089</lpage><pub-id pub-id-type="pmid">22115221</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Funatsu</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>J</given-names></name><name><surname>Nakajima</surname><given-names>H</given-names></name><name><surname>Iba</surname><given-names>Y</given-names></name><name><surname>Shimahara</surname><given-names>Y</given-names></name><name><surname>Yagihara</surname><given-names>T</given-names></name></person-group><article-title>Long-term results and reliability of cryothermic ablation based
maze procedure for atrial fibrillation concomitant with mitral valve
surgery</article-title><source>Eur J Cardiothorac Surg</source><year>2009</year><volume>36</volume><issue>2</issue><fpage>267</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">19414270</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phan</surname><given-names>K</given-names></name><name><surname>Xie</surname><given-names>A</given-names></name><name><surname>La Meir</surname><given-names>M</given-names></name><name><surname>Black</surname><given-names>D</given-names></name><name><surname>Yan</surname><given-names>T</given-names></name></person-group><article-title>Surgical ablation for treatment of atrial fibrillation in cardiac
surgery: a cumulative meta-analysis of randomized controlled
trials</article-title><source>Heart</source><year>2014</year><volume>100</volume><issue>9</issue><fpage>722</fpage><lpage>730</lpage><pub-id pub-id-type="pmid">24650881</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>SM</given-names></name><name><surname>d'Avila</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>SK</given-names></name><name><surname>Stelzer</surname><given-names>P</given-names></name><name><surname>Saad</surname><given-names>EB</given-names></name><name><surname>Skanes</surname><given-names>A</given-names></name><etal/></person-group><article-title>Clinical outcomes after repair of left atrial-esophageal fistulas
occurring after atrial fibrillation ablation procedures
Heart</article-title><source>Rhythm</source><year>2013</year><volume>10</volume><issue>11</issue><fpage>1591</fpage><lpage>1597</lpage></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cosedis Nielsen</surname><given-names>J</given-names></name><name><surname>Johannessen</surname><given-names>A</given-names></name><name><surname>Raatikainen</surname><given-names>P</given-names></name><name><surname>Hindricks</surname><given-names>G</given-names></name><name><surname>Walfridsson</surname><given-names>H</given-names></name><name><surname>Kongstad</surname><given-names>O</given-names></name><etal/></person-group><article-title>Radiofrequency ablation as initial therapy in paroxysmal atrial
fibrillation</article-title><source>N Engl J Med</source><year>2012</year><volume>367</volume><issue>17</issue><fpage>1587</fpage><lpage>1595</lpage><pub-id pub-id-type="pmid">23094720</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Damiano Jr</surname><given-names>RJ</given-names></name><name><surname>Schwartz</surname><given-names>FH</given-names></name><name><surname>Bailey</surname><given-names>MS</given-names></name><name><surname>Maniar</surname><given-names>HS</given-names></name><name><surname>Munfakh</surname><given-names>NA</given-names></name><name><surname>Moon</surname><given-names>MR</given-names></name><etal/></person-group><article-title>The Cox maze IV procedure: predictors of late
recurrence</article-title><source>J Thorac Cardiovasc Surg</source><year>2011</year><volume>141</volume><issue>1</issue><fpage>113</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">21168019</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Psychari</surname><given-names>SN</given-names></name><name><surname>Apostolou</surname><given-names>TS</given-names></name><name><surname>Santos</surname><given-names>L</given-names></name><name><surname>Hamodraka</surname><given-names>E</given-names></name><name><surname>Liakos</surname><given-names>G</given-names></name><name><surname>Kremastinos</surname><given-names>DT</given-names></name></person-group><article-title>Relation of elevated C-reactive protein and interleukin-6 levels
to left atrial size and duration of episodes in patients with atrial
fibrillation</article-title><source>Am J Cardiol</source><year>2005</year><volume>95</volume><issue>6</issue><fpage>764</fpage><lpage>767</lpage><pub-id pub-id-type="pmid">15757607</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Takeishi</surname><given-names>Y</given-names></name><name><surname>Hirono</surname><given-names>O</given-names></name><name><surname>Itoh</surname><given-names>M</given-names></name><name><surname>Matsui</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><etal/></person-group><article-title>C-reactive protein elevation predicts the occurrence of atrial
structural remodeling in patients with paroxysmal atrial
fibrillation</article-title><source>Heart Vessels</source><year>2005</year><volume>20</volume><issue>2</issue><fpage>45</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">15772777</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ducceschi</surname><given-names>V</given-names></name><name><surname>D'Andrea</surname><given-names>A</given-names></name><name><surname>Liccardo</surname><given-names>B</given-names></name><name><surname>Alfieri</surname><given-names>A</given-names></name><name><surname>Sarubbi</surname><given-names>B</given-names></name><name><surname>De Feo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Perioperative clinical predictors of atrial fibrillation
occurrence following coronary artery surgery</article-title><source>Eur J Cardiothorac Surg</source><year>1999</year><volume>16</volume><issue>4</issue><fpage>435</fpage><lpage>439</lpage><pub-id pub-id-type="pmid">10571091</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verdecchia</surname><given-names>P</given-names></name><name><surname>Angeli</surname><given-names>F</given-names></name></person-group><article-title>Natural history of hypertension subtypes</article-title><source>Circulation</source><year>2005</year><volume>111</volume><issue>9</issue><fpage>1094</fpage><lpage>1096</lpage><pub-id pub-id-type="pmid">15753224</pub-id></element-citation></ref></ref-list></back></article>